HighPoint Advisor Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.64M | Sell |
58,236
-164,565
| -74% | -$4.38M | 0.07% | 216 |
|
|
2025
Q4 | $5.55M | Buy |
222,801
+53,236
| +31% | +$1.34M | 0.12% | 147 |
|
|
2025
Q3 | $4.32M | Sell |
169,565
-67,040
| -28% | -$1.65M | 0.21% | 87 |
|
|
2025
Q2 | $5.74M | Buy |
236,605
+7,238
| +3% | +$169K | 0.3% | 56 |
|
|
2025
Q1 | $5.46M | Buy |
229,367
+27,026
| +13% | +$707K | 0.32% | 55 |
|
|
2024
Q4 | $5.18M | Sell |
202,341
-10,819
| -5% | -$293K | 0.28% | 56 |
|
|
2024
Q3 | $6.17M | Sell |
213,160
-25,177
| -11% | -$734K | 0.36% | 46 |
|
|
2024
Q2 | $7.48M | Buy |
238,337
+42,349
| +22% | +$1.17M | 0.45% | 38 |
|
|
2024
Q1 | $5.57M | Buy |
195,988
+8,787
| +5% | +$244K | 0.39% | 44 |
|
|
2023
Q4 | $5.13M | Buy |
+187,201
| New | +$5.66M | 0.37% | 49 |
|
|
2022
Q2 | $6.53M | Buy |
+123,809
| New | +$6.31M | 0.71% | 25 |
|
|
2021
Q3 | $5.94M | Buy |
138,144
+17,269
| +14% | +$765K | 0.58% | 34 |
|
|
2021
Q2 | $4.73M | Buy |
120,875
+25,753
| +27% | +$1M | 0.48% | 43 |
|
|
2021
Q1 | $3.48M | Buy |
95,122
+6,053
| +7% | +$215K | 0.4% | 53 |
|
|
2020
Q4 | $3.12M | Buy |
89,069
+15,680
| +21% | +$575K | 0.38% | 57 |
|
|
2020
Q3 | $2.53M | Buy |
73,389
+2,027
| +3% | +$71.1K | 0.46% | 52 |
|
|
2020
Q2 | $2.28M | Sell |
71,362
-4,861
| -6% | -$165K | 0.49% | 47 |
|
|
2020
Q1 | $2.7M | Sell |
76,223
-4,684
| -6% | -$160K | 0.64% | 35 |
|
|
2019
Q4 | $3.1M | Buy |
80,907
+12,995
| +19% | +$463K | 0.64% | 36 |
|
|
2019
Q3 | $2.39M | Buy |
67,912
+2,388
| +4% | +$86.8K | 0.53% | 45 |
|
|
2019
Q2 | $2.66M | Sell |
65,524
-3,912
| -6% | -$155K | 0.62% | 35 |
|
|
2019
Q1 | $2.69M | Sell |
69,436
-4,115
| -6% | -$165K | 0.66% | 37 |
|
|
2018
Q4 | $2.97M | Sell |
73,551
-261
| -0.4% | -$10.8K | 0.79% | 29 |
|
|
2018
Q3 | $3.11M | Sell |
73,812
-1,101
| -1% | -$42.4K | 0.85% | 25 |
|
|
2018
Q2 | $2.94M | Buy |
74,913
+9,353
| +14% | +$320K | 0.79% | 28 |
|
|
2018
Q1 | $2.28M | Buy |
65,560
+1,125
| +2% | +$38.7K | 0.63% | 38 |
|
|
2017
Q4 | $2.14M | Buy |
64,435
+543
| +0.8% | +$18.5K | 0.61% | 38 |
|
|
2017
Q3 | $2.15M | Buy |
63,892
+6,318
| +11% | +$203K | 0.67% | 37 |
|
|
2017
Q2 | $1.84M | Hold |
57,574
| – | – | 0.59% | 38 |
|
|
2017
Q1 | $1.84M | Buy |
57,574
+992
| +2% | +$31.3K | 0.59% | 38 |
|
|
2016
Q4 | $1.85M | Buy |
56,582
+4,989
| +10% | +$152K | 0.6% | 33 |
|
|
2016
Q3 | $1.55M | Sell |
51,593
-6,511
| -11% | -$218K | 0.55% | 40 |
|
|
2016
Q2 | $1.93M | Buy |
58,104
+29,011
| +100% | +$926K | 0.68% | 30 |
|
|
2016
Q1 | $918K | Sell |
29,093
-3,195
| -10% | -$91.3K | 0.56% | 46 |
|
|
2015
Q4 | $941K | Buy |
32,288
+14,642
| +83% | +$461K | 0.62% | 44 |
|
|
2015
Q3 | $526K | Sell |
17,646
-15,231
| -46% | -$488K | 0.58% | 68 |
|
|
2015
Q2 | $1.05M | Buy |
+32,877
| New | +$1.07M | 1.62% | 26 |
|
Other funds holding PFE
VCM
VPM
HighPoint Advisor Group's PFE Position: Q1 2026 in Review
HighPoint Advisor Group reduced its Pfizer (PFE) stake by 74% in Q1 2026, selling an estimated $4.38M and leaving 58,236 shares worth $1.64M. The position accounts for 0.07% of the portfolio, ranked #216.
HighPoint Advisor Group first reported a position in PFE in Q2 2015 and has held it in 37 quarters since. The position peaked at $7.48M in Q2 2024. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- HighPoint Advisor Group held 58,236 shares of Pfizer worth $1.64M as of Q1 2026.
- HighPoint Advisor Group sold 164,565 Pfizer shares in Q1 2026, an estimated $4.38M.
- Pfizer made up 0.07% of HighPoint Advisor Group's portfolio in Q1 2026, its #216 holding.
- HighPoint Advisor Group first reported a position in Pfizer in Q2 2015 and has held it in 37 quarters since.
- HighPoint Advisor Group's Pfizer position peaked at $7.48M in Q2 2024.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.